Sam is a trader and one of our lead stock analysts at AskTraders. After starting his career predominantly in the forex markets, Sam now focuses on gold and stocks with a preference for macroeconomic analysis.
Shares in Mallinckrodt (NYSE:MNK) have plunged premarket, wiping out earlier gains after the biopharmaceutical company reported an adjusted profit beating expectations, but also stated that it is in talks with creditors regarding a possible Chapter 11 bankruptcy filing.
In its second-quarter earnings, the company reported a net loss of $933.1 million, with a net income of $6.8 million, and a diluted loss per share of $11.04, however, its adjusted diluted earnings per share was $1.89 which represented a 25.3% decline YoY.
The main point of note from the report was in its business and litigation update where Mallinckrodt said: “The Company has identified several negative conditions and events impacting the business as of June 26, 2020.”
The continued by saying: “The ongoing opioid litigation and the Company's existing debts and the related risk of non-compliance with its financial debt covenant over the next twelve months, the Company has been working with external advisors to explore a range of options and engage in dialogue with financial creditors and litigation claimants and their advisors, including the possibility of a filing for reorganization in bankruptcy under Chapter 11 by Mallinckrodt plc and most of its subsidiaries in the near-term.”
As a result, shares in the company have plummeted premarket, by 14.60% at $1.93 per share after closing Monday trading at $2.26. It also means that Mallinckrodt shares are now down 35.24% for the year to date.
“Our reported GAAP net sales were impacted by the retrospective one-time Acthar Gel Medicaid liability, and our normalized operating results also displayed a contraction this quarter due to the COVID-19 health crisis along with increased competitive and payer pressures on certain products. Amidst these challenges, we continued to operate well, which is a testament to our employees' hard work and commitment to our business, patients and customers,” said Mark Trudeau, President and Chief Executive Officer of Mallinckrodt.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .